| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_45a3703d03a4b21be619937f5ad63b8b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425 |
| filingDate |
2004-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df81b46566ad79d63720b1bada3d9814
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09c85273e0c0149440fd919764e77482
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfcbc3f08be3724359941303c218058d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d226ab3c67650819540fd4e414541108
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bdec2d84e6c2e13193f00168d4256a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f834ed88de2324e736ac52dabec1596d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a27f5061975d35feeb02aae4a0d2879
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46f48c44ce0fc18133522045f09d8f41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d0b0ce279c5b1dd12f55103f999447a |
| publicationDate |
2006-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1694325-A2 |
| titleOfInvention |
Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses |
| abstract |
The present invention discloses compounds and pharmaceutical compositions which are highly effective at inhibiting the accumulation of spliced and unspliced viral transcripts and their utilization for viral protein synthesis at cellular ribosomes, and at inhibiting the formation of the hypusine residue in cellular eIF-5A precursor proteins, the cellular cofactors that render spliced and unspliced viral transcripts translatable at the ribosomes of infectled cells. The invention further relates to methods of using such compounds and pharmaceutical compositions therefrom for inhibiting or preventing viral protein synthesis. Such inhibition causes a dose-dependent release from the virally induced arrest of the otherwise genetically preprogrammed apoptosis of virally infected cells, and in consequence, triggers their apoptotic ablation and the eradication of the chronic infection-mediating provirus integrated into their genome. |
| priorityDate |
2003-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |